Genuity Science is bringing together a distinguished panel of experts from academia, research and industry to discuss opportunities and advancements in developing better treatments for systemic lupus erythematosus (SLE). SLE is a chronic and relapsing autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and multiorgan damage.
SLE is extremely heterogeneous in nature, with the signs and symptoms varying from person to person, which can often lead to delays in diagnosis. The treatment landscape for SLE today is comprised primarily of non-specific therapies such as antimalarials, corticosteroids, immunosuppressants and biologics. These treatments are often unsuccessful in treating the patients — particularly those with a more severe form of the disease — and longer term, these treatments can be associated with several side effects including infections, hepatotoxicity, osteoporosis and more. Episodic flares of symptoms frequently necessitate changes in medications or dosages, further complicating management of the disease.
Register for this webinar to hear an examination of why researching lupus is so complex and the fundamental challenges of SLE research. We will also explore where the field has advanced and where opportunities to deepen understanding still exist in order to accelerate the development of new drugs for this underserved group of patients.
John Dowling, Sales VP, Genuity Science
John Dowling is the Vice President of US Cohort Sales for Genuity Science. He has over 25 years of experience in drug discovery, next generation sequencing, natural language processing, AI/ML and genomic data services. John holds a M.S. degree in ALM and Biology from Harvard University and a B.S. in Mechanical Engineering from Massachusetts Maritime Academy.Message Presenter
Richard Furie, Chief, Division of Rheumatology, Northwell Health; Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell
Dr. Richard Furie, Chief of the Division of Rheumatology at Northwell Health, is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System’s clinical research program in musculoskeletal disease. He also directs the Hospital’s SLE and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE. Regarded as one of the senior rheumatologists in the New York metropolitan area, he has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. For twenty years he served on many committees of the American College of Rheumatology and was named a Master of the College in 2018. Although often featured as a speaker at national and international conferences, Dr. Furie’s favorite educational venue is at home with his colleagues and trainees.Message Presenter
Who Should Attend?
- Program lead/head of rheumatology at pharma and biotech companies
- Head of or VP/SVP translational medicine, genomics, innovation, drug discovery, technology, clinical trials at pharma companies
- Clinical researchers at hospitals and specialist consultants in rheumatology and clinical immunology
- Researchers and research leadership, head of school functions and technology transfer officers at academic institutions conducting research in genomics, genetics, systems biology, translational medicine, human health, rheumatology, and immunology
- Research institutions
- SLE patient advocacy groups
What You Will Learn
In this webinar, participants will learn about:
- Advancements and critical milestones to date in SLE research and drug discovery
- Key considerations for improving research into SLE
- Key considerations for improving drug discovery and clinical trial design for SLE
Genuity Science is a data sourcing, analytics and insights organization headquartered in Boston, Massachusetts, USA, with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity Science partners with global biopharma companies to offer deep end-to-end discovery services aimed at catalyzing precision health and improving the quality of life for patients around the world. Services include population-scale, disease-specific data sourcing, high-quality sequencing, robust statistical analysis and software tools for analyzing large datasets and artificial intelligence (AI). The company operates advanced CAP-accredited, CLIA-certified genomics laboratories in Woburn, Massachusetts, USA and in Dublin, Ireland and is deeply committed to data stewardship and data governance across its global offices. Learn more at www.genuitysci.com.
The original site for employees in the pharma, medical, diagnostic and related industries. Our hand-curated daily news feed and active message forums will keep you informed.